GSK plc (GSK)
NYSE: GSK · Pharmaceutical Preparations · London · filing with the SEC since 2001
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20269 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to GSK plc’s names, not what it holds today.
Patents granted
9
6 utility, 3 design, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
14
1 of them in 2025
Names they are printed under
3
its holding company
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology2
Pharmaceuticals2
Handling1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
GlaxoSmithKline Intellectual Property Management Limited its holding company
GB, as the owner printed on each patent; a holding company under the name GLAXOSMITHKLINE PLC
5 published
GlaxoSmithKline Intellectual Property Management Limited its holding company
named as the applicant on its applications, in GB; a holding company under the name GLAXOSMITHKLINE PLC
7 published
GlaxoSmithKline Intellectual Property Limited its holding company
named as the applicant on its applications, in GB; a holding company under the name GLAXOSMITHKLINE PLC
2 published
Names not counted (5)
GLAXOSMITHKLINE PLC
Most of its patents print US; this name counts in GB. 356 granted and 181 published under it are not counted.
GLAXOSMITHKLINE PLC
Most of its patents print US; this name counts in GB. 0 granted and 203 published under it are not counted.
GLAXOSMITHKLINE PLC
Most of its patents print IT; this name counts in GB. 3 granted and 12 published under it are not counted.
GSK plc
Most of its patents print JP; this name counts in GB. 2 granted and 1 published under it are not counted.
GLAXOSMITHKLINE PLC
Most of its patents print JP; this name counts in GB. 1 granted and 0 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| May 13, 2025 | 12,296,007 | High concentration anti-blys pharmaceutical formulations | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited |
| Aug 13, 2024 | 12,060,431 | Dosing regimen of combination of ANTICD20 and anti-BlyS antibodies | Biotechnology | GlaxoSmithKline Intellectual Property Management Limited |
| Mar 21, 2023 | D981,557 | Housing for an autoinjector | GlaxoSmithKline Intellectual Property Management Limited | |
| Feb 15, 2022 | 11,247,807 | Healthcare product package | Handling | GlaxoSmithKline Intellectual Property Management Limited |
| Nov 23, 2021 | 11,180,569 | Methods of treating autoimmune disorders using a combination of anti-CD20 and anti-blys antibodies | Biotechnology | GlaxoSmithKline Intellectual Property Management Limited |
| Nov 23, 2021 | 11,179,463 | BLyS antibody formulation | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited |
| Feb 11, 2020 | 10,556,009 | Anti-Blys antibody formulations and methods of treatment using them | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited |
| Nov 26, 2019 | D868,244 | Housing for an auto injector | GlaxoSmithKline Intellectual Property Management Limited | |
| Jun 27, 2017 | D790,686 | Housing for an autoinjector | GlaxoSmithKline Intellectual Property Management Limited |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Aug 7, 2025 | 2025/0249095 | High Concentratioin Anti-BLYS Pharmaceutical Formulations | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited |
| Oct 31, 2024 | 2024/0360237 | Dosing Regimen of Combination of Anti-CD20 and Anti-BLyS Antibodies | Biotechnology | GlaxoSmithKline Intellectual Property Management Limited |
| Aug 1, 2024 | 2024/0254247 | Anti-BAFF Antibodies for use in a Method of Treatment of Long Covid and/or Post-Acute Sequelae SARS-CoV-2 Infection (PASC) | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited |
| Jun 23, 2022 | 2022/0195062 | DOSING REGIMEN OF COMBINATION OF ANTICD20 AND ANTI-BLYS ANTIBODIES | Biotechnology | GlaxoSmithKline Intellectual Property Management Limited · patent 12,060,431 granted from it |
| Jun 9, 2022 | 2022/0175922 | ANTIBODY FORMULATION | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited · patent 12,296,007 granted from it |
| Jul 16, 2020 | 2020/0222535 | ANTIBODY FORMULATION | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited · patent 11,179,463 granted from it |
| Jan 24, 2019 | 2019/0023447 | Healthcare Product Package | Handling | GlaxoSmithKline Intellectual Property Management Limited · patent 11,247,807 granted from it |
| Oct 11, 2018 | 2018/0289804 | ANTIBODY FORMULATION | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited |
| Sep 20, 2018 | 2018/0265588 | DOSING REGIMEN OF COMBINATION OF ANTI-CD20 AND ANTI-BLYS ANTIBODIES | Biotechnology | GlaxoSmithKline Intellectual Property Management Limited · patent 11,180,569 granted from it |
| Apr 6, 2017 | 2017/0095555 | ANTIBODY FORMULATION | Pharmaceuticals | GlaxoSmithKline Intellectual Property Management Limited · patent 10,556,009 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.